Chardan reiterates Buy on Ocular Therapeutix, $23 target
Chardan Capital maintained a Buy rating on Ocular Therapeutix and set a $23.00 price target, implying 125.7% upside versus the Sep 15 close of $10.19.
00 price target. 19. Key takeaways from the analyst note included a positive regulatory outlook: Ocular Therapeutix recently had a favorable Pre-NDA meeting.